BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 23222167)

  • 21. Plasminogen activator inhibitor -1 gene 4G/5G polymorphism in patients with breast cancer.
    Eroglu A; Ulu A; Cam R; Akar N
    J BUON; 2006; 11(4):481-4. PubMed ID: 17309181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of the 4G/5G polymorphism in the promoter region of plasminogen activator inhibitor-1 with abdominal aortic aneurysms.
    Rossaak JI; Van Rij AM; Jones GT; Harris EL
    J Vasc Surg; 2000 May; 31(5):1026-32. PubMed ID: 10805895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and venous thrombosis. A meta-analysis.
    Tsantes AE; Nikolopoulos GK; Bagos PG; Rapti E; Mantzios G; Kapsimali V; Travlou A
    Thromb Haemost; 2007 Jun; 97(6):907-13. PubMed ID: 17549286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The plasminogen activator inhibitor (PAI-1) 4G/5G promoter polymorphism and PAI-1 levels in ischemic stroke. A case-control study.
    van Goor ML; Gómez García E; Leebeek F; Brouwers GJ; Koudstaal P; Dippel D
    Thromb Haemost; 2005 Jan; 93(1):92-6. PubMed ID: 15630497
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism, coronary thrombosis, and myocardial infarction in middle-aged Finnish men who died suddenly.
    Mikkelsson J; Perola M; Wartiovaara U; Peltonen L; Palotie A; Penttilä A; Karhunen PJ
    Thromb Haemost; 2000 Jul; 84(1):78-82. PubMed ID: 10928474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history.
    Jorgenson E; Deitcher SR; Cicek M; Liu X; Plummer S; Casey G; Witte JS
    Prostate; 2007 Feb; 67(2):172-7. PubMed ID: 17044080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allele 4G of gene PAI-1 associated with prothrombin mutation G20210A increases the risk for venous thrombosis.
    Barcellona D; Fenu L; Cauli C; Pisu G; Marongiu F
    Thromb Haemost; 2003 Dec; 90(6):1061-4. PubMed ID: 14652637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genotype frequency of plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism in healthy Japanese males and its relation to PAI-1 levels.
    Matsubara Y; Murata M; Isshiki I; Watanabe R; Zama T; Watanabe G; Watanabe K; Ikeda Y
    Int J Hematol; 1999 Jan; 69(1):43-7. PubMed ID: 10641442
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.
    Castelló R; España F; Vázquez C; Fuster C; Almenar SM; Aznar J; Estellés A
    Thromb Res; 2006; 117(5):487-92. PubMed ID: 15907980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of plasminogen activator inhibitor-1 (SERPINE1) 4G/5G polymorphism on circulating SERPINE-1 antigen expression in HCC associated with viral infection.
    Divella R; Mazzocca A; Gadaleta C; Simone G; Paradiso A; Quaranta M; Daniele A
    Cancer Genomics Proteomics; 2012; 9(4):193-8. PubMed ID: 22798504
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of decreased fibrinolytic activity and plasminogen activator inhibitor-1 4G/5G polymorphism on the risk of venous thrombosis.
    Vuckovic BA; Djeric MJ; Tomic BV; Djordjevic VJ; Bajkin BV; Mitic GP
    Blood Coagul Fibrinolysis; 2018 Jan; 29(1):19-24. PubMed ID: 28777103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasminogen activator inhibitor-1 4G/5G polymorphism, factor V Leiden, prothrombin mutations and the risk of VTE recurrence.
    Sundquist K; Wang X; Svensson PJ; Sundquist J; Hedelius A; Larsson Lönn S; Zöller B; Memon AA
    Thromb Haemost; 2015 Nov; 114(6):1156-64. PubMed ID: 26245493
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Relationship between plasminogen activator inhibitor-1 gene 4G/5G polymorphism and type 2 diabetic nephropathy in Chinese Han patients in Guangdong Province].
    Liu SQ; Xue YM; Yang GC; He FY; Zhao XS
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Aug; 24(8):904-7. PubMed ID: 15321757
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A common 4G allele in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene as a risk factor for pulmonary embolism and arterial thrombosis in hereditary protein S deficiency.
    Zöller B; García de Frutos P; Dahlbäck B
    Thromb Haemost; 1998 Apr; 79(4):802-7. PubMed ID: 9569196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer.
    Błasiak J; Smolarz B
    Acta Biochim Pol; 2000; 47(1):191-9. PubMed ID: 10961693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PAI-1 4G/5G gene polymorphism is associated with angiographic patency in ST-elevation myocardial infarction patients treated with thrombolytic therapy.
    Ozkan B; Cagliyan CE; Elbasan Z; Uysal OK; Kalkan GY; Bozkurt M; Tekin K; Bozdogan ST; Ozalp O; Duran M; Sahin DY; Cayli M
    Coron Artery Dis; 2012 Sep; 23(6):400-3. PubMed ID: 22850480
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation between plasminogen activator inhibitor-1 4G/5G polymorphism and pre-eclampsia: an appraisal.
    Wiwanitkit V
    Arch Gynecol Obstet; 2006 Mar; 273(6):322-4. PubMed ID: 16502012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between gene polymorphism of the PAI-1 promoter and myocardial infarction.
    Fu L; Jin H; Song K; Zhang C; Shen J; Huang Y
    Chin Med J (Engl); 2001 Mar; 114(3):266-9. PubMed ID: 11780311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of plasminogen activator inhibitor-1 gene 4G/5G polymorphism on glucose and lipid metabolisms in Turkish obese children.
    Kinik ST; Ataç FB; Verdi H; Cetintaş S; Sahin FI; Ozbek N
    Clin Endocrinol (Oxf); 2005 May; 62(5):607-10. PubMed ID: 15853833
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PAI-1 4G/5G insertion/deletion promoter polymorphism and microvascular complications in type 2 diabetes mellitus.
    Funk M; Endler G; Exner M; Marculescu R; Endler L; Abrahamian H; Mauler H; Grimm A; Raith M; Mannhalter C; Prager R; Irsigler K; Wagner OF
    Wien Klin Wochenschr; 2005 Oct; 117(19-20):707-10. PubMed ID: 16416371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.